Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis

• Benign metastasizing leiomyomatosis (BML) is a rare condition. • Treatment options have traditionally included surgical resection or hormonal based therapy. • Traditional chemotherapy for BML is ineffective. • Our patient has had a prolonged response of stable disease with the anti-VEGF therapy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Chhabra, Shalini, Sangani, Pooja, Saig, Reagan, Stany, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068955/
https://www.ncbi.nlm.nih.gov/pubmed/35531358
http://dx.doi.org/10.1016/j.gore.2021.100903
_version_ 1784700330643030016
author Chhabra, Shalini
Sangani, Pooja
Saig, Reagan
Stany, Michael
author_facet Chhabra, Shalini
Sangani, Pooja
Saig, Reagan
Stany, Michael
author_sort Chhabra, Shalini
collection PubMed
description • Benign metastasizing leiomyomatosis (BML) is a rare condition. • Treatment options have traditionally included surgical resection or hormonal based therapy. • Traditional chemotherapy for BML is ineffective. • Our patient has had a prolonged response of stable disease with the anti-VEGF therapy of bevacizumab.
format Online
Article
Text
id pubmed-9068955
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-90689552022-05-05 Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis Chhabra, Shalini Sangani, Pooja Saig, Reagan Stany, Michael Gynecol Oncol Rep Case Report • Benign metastasizing leiomyomatosis (BML) is a rare condition. • Treatment options have traditionally included surgical resection or hormonal based therapy. • Traditional chemotherapy for BML is ineffective. • Our patient has had a prolonged response of stable disease with the anti-VEGF therapy of bevacizumab. Elsevier 2021-12-18 /pmc/articles/PMC9068955/ /pubmed/35531358 http://dx.doi.org/10.1016/j.gore.2021.100903 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Chhabra, Shalini
Sangani, Pooja
Saig, Reagan
Stany, Michael
Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title_full Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title_fullStr Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title_full_unstemmed Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title_short Prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
title_sort prolonged response with bevacizumab in a patient with benign metastasizing leiomyomatosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068955/
https://www.ncbi.nlm.nih.gov/pubmed/35531358
http://dx.doi.org/10.1016/j.gore.2021.100903
work_keys_str_mv AT chhabrashalini prolongedresponsewithbevacizumabinapatientwithbenignmetastasizingleiomyomatosis
AT sanganipooja prolongedresponsewithbevacizumabinapatientwithbenignmetastasizingleiomyomatosis
AT saigreagan prolongedresponsewithbevacizumabinapatientwithbenignmetastasizingleiomyomatosis
AT stanymichael prolongedresponsewithbevacizumabinapatientwithbenignmetastasizingleiomyomatosis

Ejemplares similares